patent/CN-102952168-A

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102952168-A

Outgoing Links

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c6ed83b9d5c28c6c356d1d08d58501e7
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J41-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-567 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J13-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J71-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-365
filingDate	2012-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_197836c8470c1e6c6681fd04123d26f1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51a32ce7e1c51819e7ccd4b10cce8124 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_65317bd0de1e28a8820e27a82c434dcc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c225bbbf63809047d4c5687bed3573e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36f0d64229f35139e77b22638a3307df http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e978a716030272ba7bd0cde289cb59d
publicationDate	2013-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	CN-102952168-A
titleOfInvention	A class of estrogen derivatives as blood vessel inhibitors, its preparation method and medical use
abstract	The present invention relates to the field of medicinal chemistry, in particular to estrogen derivatives of general formula (I), their pharmaceutically acceptable salts, their preparation methods and their medical uses, the compounds of the present invention and their pharmaceutically acceptable The salt is used for the treatment of pathological angiogenesis-related diseases such as tumors, retinopathy, rheumatoid arthritis, diabetes, lupus erythematosus, chronic inflammatory reactions and the like. For the definition of each group in the formula, see the description for details.
isCitedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104188974-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104188974-B
priorityDate	2012-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate	Subject
isCitedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8288367-B2
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID468142291 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466731356 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465210312 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID163598769

Total number of triples: 36.